On Wednesday, the PSX extended its bullish run as sustained buying interest propelled the benchmark index to a fresh all-time ...
In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback